Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.

Norberto Giglio, Angela Gentile, Lydia Lees, Paula Micone, Judith Armoni, Camille Reygrobellet, Pascal Crépey
Author Information
  1. Norberto Giglio: Epidemiología Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

Abstract

BACKGROUND: Argentina's population was heavily affected by the 2009 influenza pandemic, particularly children, in whom incidence of seasonal influenza is consistently high. Following the pandemic, Argentinean national recommendations for pediatric vaccination against A/H1N1 influenza were defined for all children aged up to five years, in line with programs implemented by national authorities elsewhere. Economic evaluations have found that vaccination programs for this population against seasonal influenza are cost-effective, if not cost-saving in many countries. Recently, Argentina decided to routinely vaccinate against influenza children aged 6-23 mo-old. But, the economic value of such strategies for the country has never been assessed.
METHODS: A model was developed to assess the value of four different vaccination strategies: (1) no pediatric vaccination; (2) vaccination of 6-23 mo-old children; (3) vaccination of 6-36 mo-old children; (4) vaccination of 6 mo-5 y-old children. We first estimated community health benefits of vaccination then we evaluated the economic and quality-of-life impact of these strategies on the population. Data used in the model come from surveillance networks, published literature, national databases and retrospective hospital-based data.
RESULTS: Pediatric influenza vaccination benefited not only children but also the overall community, due to decreased disease transmission. Our results showed that the recent decision by Argentina to vaccinate 6-23 mo-old children is cost-effective as would be the incremental vaccination of broader age groups.
CONCLUSIONS: Results from this study are consistent with previous analyses in other countries confirming that implementing influenza pediatric vaccination programs can be highly cost-effective through individual- and community protection against the disease.

References

  1. Am J Epidemiol. 1976 Feb;103(2):152-65 [PMID: 814808]
  2. JAMA. 2010 Mar 10;303(10):943-50 [PMID: 20215608]
  3. Vaccine. 2007 Nov 19;25(47):8010-20 [PMID: 17936446]
  4. Vaccine. 2001 Jul 20;19(30):4204-13 [PMID: 11457546]
  5. Value Health. 2008 Mar-Apr;11(2):160-71 [PMID: 18380629]
  6. Pediatr Infect Dis J. 2007 Feb;26(2):97-106 [PMID: 17259870]
  7. Vaccine. 2006 Jun 5;24(23):4934-41 [PMID: 16678945]
  8. N Engl J Med. 2010 Jan 7;362(1):45-55 [PMID: 20032320]
  9. PLoS One. 2011 Mar 02;6(3):e17030 [PMID: 21399678]
  10. J Gen Intern Med. 2003 Oct;18(10):808-15 [PMID: 14521643]
  11. Vaccine. 2005 Apr 22;23(22):2851-61 [PMID: 15780733]
  12. Vaccine. 2002 Sep 10;20(27-28):3254-62 [PMID: 12213394]
  13. Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170 [PMID: 14609480]
  14. Lancet. 2005 Oct 1;366(9492):1165-74 [PMID: 16198765]
  15. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004876 [PMID: 16856068]
  16. Value Health. 2009 Jun;12(4):587-96 [PMID: 19900257]
  17. Vaccine. 2002 Mar 15;20(13-14):1831-6 [PMID: 11906772]
  18. Vaccine. 2004 Sep 3;22(25-26):3475-86 [PMID: 15308375]
  19. Vaccine. 2010 Mar 8;28(11):2302-10 [PMID: 20064478]
  20. Vaccine. 2005 Jan 26;23(10):1284-93 [PMID: 15652671]
  21. J Public Health Policy. 2009 Apr;30(1):83-101 [PMID: 19367303]
  22. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD001269 [PMID: 17443504]
  23. Am J Epidemiol. 1985 Jun;121(6):811-22 [PMID: 4014174]
  24. Bull World Health Organ. 1969;41(3):537-42 [PMID: 5309469]
  25. Emerg Infect Dis. 2006 Oct;12(10):1548-58 [PMID: 17176570]
  26. N Engl J Med. 2007 Oct 4;357(14):1373-81 [PMID: 17914038]
  27. Vaccine. 2000 Mar 17;18(18):1902-9 [PMID: 10699339]
  28. Pharmacoeconomics. 2008;26(2):163-78 [PMID: 18198935]
  29. Pediatr Infect Dis J. 2008 Nov;27(11 Suppl):S154-8 [PMID: 18955891]
  30. Vaccine. 2006 Nov 17;24(47-48):6812-22 [PMID: 17034909]
  31. PLoS Med. 2008 Mar 25;5(3):e74 [PMID: 18366252]

MeSH Term

Adolescent
Adult
Aged
Aged, 80 and over
Argentina
Child
Child, Preschool
Costs and Cost Analysis
Female
Humans
Immunization Programs
Infant
Infant, Newborn
Influenza Vaccines
Influenza, Human
Male
Middle Aged
Vaccination
Young Adult

Chemicals

Influenza Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccinationinfluenzachildrenpediatricprogramsmo-oldpopulationnationalcost-effectiveArgentina6-23economiccommunitypandemicseasonalagedcountriesvaccinatevaluestrategiesmodelhealthbenefitsdiseaseBACKGROUND:Argentina'sheavilyaffected2009particularlyincidenceconsistentlyhighFollowingArgentineanrecommendationsA/H1N1definedfiveyearslineimplementedauthoritieselsewhereEconomicevaluationsfoundcost-savingmanyRecentlydecidedroutinelycountryneverassessedMETHODS:developedassessfourdifferentstrategies:1236-3646mo-5y-oldfirstestimatedevaluatedquality-of-lifeimpactDatausedcomesurveillancenetworkspublishedliteraturedatabasesretrospectivehospital-baseddataRESULTS:PediatricbenefitedalsooverallduedecreasedtransmissionresultsshowedrecentdecisionincrementalbroaderagegroupsCONCLUSIONS:Resultsstudyconsistentpreviousanalysesconfirmingimplementingcanhighlyindividual-protectionPublicnew

Similar Articles

Cited By